Which pharmacy makes your compounded GLP-1? Only 2 of 13 name it

Most GLP-1 telehealth programs won't name the pharmacy that makes your compounded drug. We checked all 13. Only two name it.

By John Samaras, EditorAug 24, 20264 min read

Of the 13 GLP-1 telehealth programs we track, only two will name the pharmacy that makes their compounded drug. Most of the rest hide behind "a licensed compounding pharmacy." That matters. When a compounding pharmacy gets a recall or an FDA warning, the fallout lands on you, not the brand you bought from, and you can't check a pharmacy nobody named.

Every pharmacy name below is sourced to the program's own materials or a public regulatory record. Where a program won't say, we mark it "Not disclosed." Some links here earn us a commission.

Who makes your compounded GLP-1

ProgramCompounding pharmacyTypeHow we know
MochiAequita Pharmacy (since closed)503AMochi's own blog, a Washington state stop-service order, and an FDA recall
SesameMedivant compounds, Foothills ships503BSesame's own clinician help doc
FoundNot disclosed503ASays it uses 503A pharmacies, names none
LemonaidNot disclosed503BA 23andMe press release says 503B, names none
Henry MedsNot disclosedNot stated"Licensed compounding pharmacies in the US"
ShedNot disclosedNot stated"Made by a licensed pharmacy"
StrutNot disclosedNot statedFDA warning letter, February 2026
MedviNot disclosedNot statedFDA warning letter, February 2026; names it only at intake
IvimNot disclosedNot statedFDA warning letter, February 2026; "on request" only
HoneNot disclosedNot stated"Network of trusted pharmacies"
Noom MedNot disclosedNot stated"Designated partner pharmacies"
Push HealthYou choose the pharmacyVariesMarketplace; your prescriber sends the script to your pharmacy
9amHealthBranded, not compoundedN/APrescribes FDA-approved GLP-1s to a retail pharmacy

Two name a pharmacy. Nine sell compounded and won't say which. Two do not compound at all.

Why the pharmacy behind your drug matters

Compounded semaglutide is not made by Novo Nordisk. A compounding pharmacy mixes it to a prescription. When that pharmacy has a problem, the patient wears it. Mochi is the clearest case. Its compounder, Aequita Pharmacy of Kirkland, Washington, drew a state stop-service order and an FDA Class II recall of its compounded semaglutide in 2025, and has since closed. Anyone with the pharmacy name could have pulled those records before buying. Mochi's customers were never given it, and Mochi's site does not name a current pharmacy.

What 503A and 503B mean

A 503A pharmacy compounds one prescription for one patient. A 503B outsourcing facility makes larger batches and registers with the FDA, which inspects it on a schedule. Neither product is FDA-approved, but a 503B carries more routine oversight. Found says it uses 503A pharmacies. A 23andMe press release said Lemonaid's semaglutide comes from a 503B. Sesame's help doc names Medivant, a registered 503B. Most programs won't even tell you which category applies to your dose.

The FDA already flagged three of them

On one day, February 20, 2026, the FDA sent warning letters to Strut, Medvi and Ivim (references 721448, 721455 and 721816, searchable on the FDA warning-letter database). All three letters flagged the same thing. Their labeling and marketing implied the telehealth brand was the compounder when it is not, and in places implied the compounded drug was FDA-approved. None of the three names its pharmacy on its site.

What to do before you buy

Ask the program to name the compounding pharmacy in writing. A program that will tell you is one you can check. Search that pharmacy on the FDA's databases and your state board of pharmacy for recalls or discipline. If a program won't name it at all, treat that as its own answer.

Compare all-in prices and lock-in terms across every program on our chart, or start with the compounded GLP-1 guide.

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.